Syon Capital LLC Purchases 3,678 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Syon Capital LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 25.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 18,079 shares of the biopharmaceutical company's stock after purchasing an additional 3,678 shares during the quarter. Syon Capital LLC's holdings in Gilead Sciences were worth $1,670,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in GILD. Westside Investment Management Inc. lifted its holdings in Gilead Sciences by 3.5% during the third quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company's stock worth $2,249,000 after acquiring an additional 917 shares during the period. SkyView Investment Advisors LLC raised its stake in shares of Gilead Sciences by 5.4% during the 3rd quarter. SkyView Investment Advisors LLC now owns 8,482 shares of the biopharmaceutical company's stock worth $711,000 after purchasing an additional 435 shares during the period. Pine Valley Investments Ltd Liability Co purchased a new position in shares of Gilead Sciences in the 3rd quarter worth about $209,000. World Investment Advisors LLC grew its position in Gilead Sciences by 33.6% during the third quarter. World Investment Advisors LLC now owns 25,999 shares of the biopharmaceutical company's stock valued at $2,180,000 after buying an additional 6,535 shares during the period. Finally, Arvest Bank Trust Division purchased a new stake in Gilead Sciences during the third quarter worth about $9,661,000. 83.67% of the stock is owned by institutional investors.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $118.17, for a total value of $2,118,669.93. Following the sale, the chief financial officer now directly owns 169,061 shares in the company, valued at $19,977,938.37. The trade was a 9.59 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last ninety days, insiders sold 302,785 shares of company stock valued at $30,540,875. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD traded down $2.98 during midday trading on Friday, hitting $103.17. 14,207,970 shares of the stock traded hands, compared to its average volume of 7,526,289. The firm has a 50-day moving average of $109.21 and a two-hundred day moving average of $98.15. The firm has a market capitalization of $128.46 billion, a P/E ratio of 278.84, a PEG ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.73 by $0.08. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter in the prior year, the business posted ($1.32) earnings per share. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 3.06%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's payout ratio is currently 854.05%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on GILD shares. Royal Bank of Canada raised their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. Oppenheimer dropped their price target on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday. Piper Sandler lifted their price objective on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, February 12th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Friday. Nine analysts have rated the stock with a hold rating, sixteen have issued a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $108.42.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.